AACR moves in a myeloid direction

A survey of the hot topics covered in this year’s AACR abstracts

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses.

One of those ways is by manipulating the microbiome -- another standout topic among this year’s abstracts -- to take advantage of the microbiome’s impact on immune cell populations in the tumor microenvironment.

In its fourth annual analysis, BioCentury surveyed the 5,030 abstracts published in advance of the American Association for Cancer Research (AACR) meeting, which will take place March 29-April 3 in Atlanta.

The survey identifies 25 new and 45 emerging targets and documents a shift towards myeloid cells, where researchers are finding ways to either block these immunosuppressive cells or convert them to active agents that could boost the potency of the first generation of T cell based therapies.

The momentum is now on strategies to convert the immunosuppressive tumor microenvironment to an immunostimulatory one.

The trend suggests the research community is moving forward from a major theme that has run through the conference, and the industry, over the past few years, which is to design cell therapies, such as CAR Ts, to kill cancer cells.

The momentum is now on strategies to convert the immunosuppressive tumor microenvironment to an immunostimulatory one.

This year’s abstracts also show progress in deploying the microbiome to manipulate antitumor immunity. Instead of focusing largely on gut microbiome-derived prognostic markers, as has been the case in previous years, the new studies focus on therapeutic interventions targeting the body’s various microbiomes, including the microbial community inside the tumors themselves.

Other abstracts show a rising interest in nanoparticle-based formulations of cancer therapies, reflecting the expansion of new modalities such as nucleic acid-based therapies and oncolytic viruses that depend on such delivery mechanisms.

The survey also points to a few emerging areas to watch in cancer, including targeted protein degradation and chromatin remodeling, and finds a slight dip in breast cancer’s dominance over other indications.

Myeloid in focus

An interest in myeloid cells is apparent across BioCentury’s analyses. The surge in abstracts discussing myeloid cell subsets suggests the research community is drilling down to the targets that might improve immunotherapy responses.

Myeloid cells are particularly interesting tumor microenvironment targets because they exist in both immunosuppressive and immunostimulatory forms, often classed as M2 and M1 macrophages, respectively. Converting from the former to the latter takes the brakes off the immune system and steps on the gas at the same time (see “Flipping the Switch in Immuno-oncology”).

The number of abstracts covering T cell therapies

Read the full 4243 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE